Overview

Efficacy and Safety of Telitacicept in IgAN

Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
A study to evaluate efficacy and safety of telitacicept in the treatment of patients with primary IgA nephropathy at high risk of progression.
Phase:
NA
Details
Lead Sponsor:
Ruijin Hospital
Collaborators:
Huashan Hospital
RenJi Hospital
Renmin Hospital of Wuhan University
Shanghai 6th People's Hospital
Shanghai Changzheng Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Longhua Hospital
Sichuan Provincial People's Hospital
Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Wannan Medical College Yijishan Hospital
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Treatments:
Glucocorticoids
telitacicept